REPL Replimune Group, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737953 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.6%
TTM EPS YoY19.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-115.8%
ROA-71.0%
ROIC (approx.)-209.7%
Asset turnover—
Leverage & solvency
Liabilities / assets45.2%
Debt / equity0.49x
Current ratio7.11x
Interest coverage-30.18x
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $221.18M | $189.45M | $174.96M | $126.53M | $79.55M |
| SG&A expense | $98.73M | $72.18M | $59.81M | $50.55M | $38.77M |
| Operating income | -$319.92M | -$261.63M | -$234.77M | -$177.08M | -$118.31M |
| Interest expense | $6.80M | $5.78M | $4.50M | $1.96M | $0 |
| Pretax income | -$314.49M | -$246.83M | -$215.39M | -$174.00M | -$118.04M |
| Income tax | -$551,000 | $468,000 | $408,000 | $288,000 | $0 |
| Net income | -$313.94M | -$247.30M | -$215.79M | -$174.28M | -$118.04M |
| EBITDA | -$316.59M | -$258.12M | -$232.12M | -$174.63M | -$116.17M |
| EPS (basic) | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 |
| EPS (diluted) | -3.38 | -3.07 | -3.24 | -2.99 | -2.26 |
| Weighted avg. shares (diluted) | 92.80M | 80.56M | 66.57M | 58.21M | 52.21M |
| Balance sheet | |||||
| Cash & equivalents | $209.02M | $112.82M | $76.16M | $148.23M | $107.58M |
| Short-term investments | $59.87M | $372.69M | $346.21M | $436.80M | $289.71M |
| Inventory | $0 | — | — | — | — |
| Current assets | $279.12M | $495.88M | $433.67M | $592.60M | $403.98M |
| PP&E, net | $12.97M | $13.74M | $10.48M | $7.48M | $7.93M |
| Total assets | $332.39M | $551.33M | $487.72M | $646.59M | $461.19M |
| Current liabilities | $58.23M | $62.36M | $40.44M | $33.83M | $20.76M |
| Long-term debt | $83.31M | $46.38M | $44.81M | $28.65M | $0 |
| Total debt | $83.31M | $46.38M | $44.81M | $28.65M | $0 |
| Total liabilities | $166.23M | $135.49M | $113.21M | $91.30M | $49.96M |
| Shareholders' equity | $166.16M | $415.84M | $374.51M | $555.29M | $411.23M |
| Net debt | -$125.72M | -$66.44M | -$31.35M | -$119.58M | -$107.58M |
| Shares outstanding | 82.72M | 77.09M | 61.42M | 56.68M | 47.34M |
| Cash flow statement | |||||
| Operating cash flow | -$280.34M | -$192.25M | -$185.47M | -$128.05M | -$82.18M |
| Capital expenditure | $4.22M | $6.69M | $5.66M | $2.27M | $2.34M |
| Free cash flow | -$284.57M | -$198.94M | -$191.13M | -$130.32M | -$84.52M |
| Investing cash flow | $310.84M | -$23.80M | $97.20M | -$142.50M | -$1.81M |
| Financing cash flow | $66.29M | $252.40M | $16.28M | $311.30M | $6.60M |
| Depreciation & amortization | $3.33M | $3.50M | $2.65M | $2.45M | $2.15M |
| Stock-based compensation | $32.27M | $35.04M | $34.12M | $28.13M | $24.25M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.